Compare GTIM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | ICU |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.9M |
| IPO Year | 1990 | N/A |
| Metric | GTIM | ICU |
|---|---|---|
| Price | $1.14 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.0K | ★ 2.3M |
| Earning Date | 12-23-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.03 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $143,398,000.00 | $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | $9.63 | ★ N/A |
| Revenue Growth | 1.78 | ★ 1195.59 |
| 52 Week Low | $1.10 | $0.22 |
| 52 Week High | $2.65 | $3.07 |
| Indicator | GTIM | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 32.77 |
| Support Level | $1.24 | $0.23 |
| Resistance Level | $1.35 | $0.28 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 10.94 | 19.24 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.